{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-25-032232","form_type":"8-K","ticker":"AVTX","cik":"0001534120","company_name":"Avalo Therapeutics, Inc.","filed_at":"2025-06-20T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.664107+00:00","generated_at":"2026-05-19T01:20:01.151465+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"confidence":"medium","headline":"Avalo posts updated investor presentation highlighting IL-1β pipeline focus","bullets":["Presentation dated June 2025 reiterates mission to advance novel IL-1β therapies for unmet medical needs.","No new clinical data, financial results, or guidance included in the investor deck.","Company to use presentation in meetings with investors; no material change in strategy disclosed."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-25-032232","json":"https://secwatch.observer/filing/0001628280-25-032232.json","markdown":"https://secwatch.observer/filing/0001628280-25-032232.md","text":"https://secwatch.observer/filing/0001628280-25-032232.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1534120/000162828025032232/0001628280-25-032232-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1534120/000162828025032232/avtx-20250620.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-19T01:20:01.151465+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}